September 21, 2026
The promise of cell and gene therapies is big. They have the ability to address the underlying genetic causes of disease, offering new possibilities for people with serious and previously difficult-to-treat conditions. But as cell and gene therapies move beyond just treating rare diseases to also address conditions such as high cholesterol, the market is being shaped by new questions about access and value. The evidence base for existing therapies also continues to evolve, particularly as researchers assess long-term outcomes for treatments that are often approved based on small patient datasets.
Sarah Emond, President and CEO of the Institute for Clinical and Economic Review (ICER), returns to the Business Group on Health podcast to discuss what has changed in the cell and gene therapy market. The conversation explores evolving evidence, how therapies are priced and paid for, provider capacity, regulatory developments, and the long-term durability of treatment outcomes.
As the number of people who become eligible for cell and gene therapies grows, employers face the challenge of connecting employees and their families to potentially life-changing therapies, while also assessing value and managing financial risk.
Tune in for practical insights into new developments, emerging payment options and how stakeholders across the healthcare ecosystem can work together to balance innovation, access and affordability.
SPEAKERS
Sarah Emond | President and CEO, Institute for Clinical and Economic Review (ICER)
Ellen Kelsay | President and CEO, Business Group on Health
Duration 33 min
